Lecture Summary - ASCO 2022 on the Phase 2/3 Study of an Individualized Neoantigen Vaccine + Immune Checkpoint Blockade as Maintenance for Newly Diagnosed mCRC

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

10 seconds

Playback speed

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

Lecture Summary - ASCO 2022 on the Phase 2/3 Study of an Individualized Neoantigen Vaccine + Immune Checkpoint Blockade as Maintenance for Newly Diagnosed mCRC

By ASCO 2022 Conference Coverage FEATURING J. Randolph Hecht

53 views

June 13, 2022

Comments 0

Hypothetical Patient Case: Hepatocellular Carcinoma with Progression…

Feat. J. Gutierrez, J. Strauss

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Feat. K. Hanna, J. Strauss

Colorectal Cancer Webinar

Thu, Mar 27, 2025

See 1 other

Yale Cancer Center

Gastroesophageal Cancer Webinar

Thu, Apr 24, 2025

The Immuno-Oncology Clinical Network (IOCN)

Advancing the Management of Immunotherapy Toxicities Through Case Co…

Fri, Mar 21, 2025

Total Health

Cancer Updates GI and Lung

Thu, Mar 13, 2025

See 1 other

Total Health

Best of ASCO GI Cancer

Sat, Apr 5, 2025

Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

2.8K views

GI Cancers: Hot Topics in 2024

Yale Cancer Center

J. Lacy

1.8K views

Year in Review 2024 - Colorectal Cancer

Oncology 2024 Year in Review

R. Kim, T. Biachi

669 views

ESMO 2024 Summary: Late-Line Therapy in mCRC - How to Choose

2024 ESMO Annual Meeting Insights Hub

H. Hochster

620 views

New

ASCO® GI 2025 Insights: Ph3 BREAKWATER Study - Encorafenib + Cetuxim…

Insights from 2025 ASCO® GI Annual Meeting

S. Kopetz

184 views

ASCO® GI 2025 Insights: CheckMate 8HW - First Results of Nivo + Ipi …

Insights from 2025 ASCO® GI Annual Meeting

T. André

251 views

ESMO 2024 Summary: Neoadjuvant Colon Cancer Treatment - Recent Clini…

2024 ESMO Annual Meeting Insights Hub

J. Taieb

420 views

The Importance of 1L Biomarkers in CRC

Nicholas DeVito

771 views

ASCO® GI 2025 Insights: Encorafenib + Cetuximab +/- Binimetinib in B…

Insights from 2025 ASCO® GI Annual Meeting

Y. Sunakawa

150 views

New

ASCO® GI 2025 Insights: Uses of Bevacizumab in Appendiceal Adenocarc…

Insights from 2025 ASCO® GI Annual Meeting

J. Shen

141 views

ESMO 2024 Summary: Highlights in CRC and Impacts on Practice

2024 ESMO Annual Meeting Insights Hub

R. Kim, T. Biachi

300 views

1L Botensilimab + Balstilimab in Stage IV MSS CRC Without Liver Mets…

Nicholas DeVito

206 views

New

ASCO® GI 2025 Summary: Meta-Analysis of Phase II/III RCTs to Evaluat…

Insights from 2025 ASCO® GI Annual Meeting

K. Thein

168 views

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

327 views

Infectious Disease Perspective of CAR T-Cell Therapy

Moffitt Cancer Center

A. Baluch

108 views

New

ASCO® GI 2025 Summary: Meta-Analysis of Phase II/III RCTs to Evaluat…

Insights from 2025 ASCO® GI Annual Meeting

K. Thein

114 views

ASCO® GI 2025 Insights: Preoperative Botensilimab +/- Balstilimab in…

Insights from 2025 ASCO® GI Annual Meeting

F. Ghelardi

81 views

ASCO® 2024 Summary: "CRC Key Studies Including TRANSMET, CheckMate 8…

2024 ASCO® Annual Meeting Insights Hub

R. Kim, T. Biachi

586 views

ASCO® 2024 Precision Medicine Highlights: LAURA and CROWN Trials (NS…

2024 ASCO® Annual Meeting Insights Hub

V. Subbiah

690 views

Clinical Implications of Tumor Agnostic Therapies

Shivaani Kummar

336 views

AUTOPLAY

Login

Login

Join VuMedi

Lecture Summary - ASCO 2022 on the Phase 2/3 Study of an Individualized Neoantigen Vaccine + Immune Checkpoint Blockade as Maintenance for Newly Diagnosed mCRC

Hypothetical Patient Case: Hepatocellular Carcinoma with Progression…

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Related Videos

Colorectal Cancer Webinar

Gastroesophageal Cancer Webinar

Advancing the Management of Immunotherapy Toxicities Through Case Co…

Cancer Updates GI and Lung

Best of ASCO GI Cancer

Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

GI Cancers: Hot Topics in 2024

Year in Review 2024 - Colorectal Cancer

ESMO 2024 Summary: Late-Line Therapy in mCRC - How to Choose

ASCO® GI 2025 Insights: Ph3 BREAKWATER Study - Encorafenib + Cetuxim…

ASCO® GI 2025 Insights: CheckMate 8HW - First Results of Nivo + Ipi …

ESMO 2024 Summary: Neoadjuvant Colon Cancer Treatment - Recent Clini…

The Importance of 1L Biomarkers in CRC

ASCO® GI 2025 Insights: Encorafenib + Cetuximab +/- Binimetinib in B…

ASCO® GI 2025 Insights: Uses of Bevacizumab in Appendiceal Adenocarc…

ESMO 2024 Summary: Highlights in CRC and Impacts on Practice

1L Botensilimab + Balstilimab in Stage IV MSS CRC Without Liver Mets…

ASCO® GI 2025 Summary: Meta-Analysis of Phase II/III RCTs to Evaluat…

ESMO 2024 Summary: Developmental Therapeutics Highlights

Infectious Disease Perspective of CAR T-Cell Therapy

ASCO® GI 2025 Summary: Meta-Analysis of Phase II/III RCTs to Evaluat…

ASCO® GI 2025 Insights: Preoperative Botensilimab +/- Balstilimab in…

ASCO® 2024 Summary: "CRC Key Studies Including TRANSMET, CheckMate 8…

ASCO® 2024 Precision Medicine Highlights: LAURA and CROWN Trials (NS…

Clinical Implications of Tumor Agnostic Therapies